continued New Faculty 32 Troy A. McEachron, Ph.D. Troy A. McEachron, Ph.D., has been appointed as a Tenure-Track Investigator in the Pediatric Oncology Branch and is a member of the NIH Distinguished Scholars Program. Dr. McEachron leads the Integrated Solid Tumor Biology Section where his team is using various molecular and cellular tools and technology platforms to dissect the metastatic osteosarcoma microenvironment and identify actionable therapeutic targets for clinical translation. Anandani Nellan, M.D., M.P.H. Anandani Nellan, M.D., M.P.H., has joined the Pediatric Oncology Branch as part of CCR’s Physician-Scientist Early Investigator Program and is a member of the NIH Distinguished Scholars Program. Dr. Nellan is a pediatric neuro-oncologist specializing in pediatric hematology-oncology and neuro-oncology. Her primary goal is to pioneer new immunotherapies for pediatric brain tumors. Rosa Nguyen, M.D., Ph.D. Rosa Nguyen, M.D., Ph.D., has joined the Pediatric Oncology Branch as part of CCR’s Physician-Scientist Early Investigator Program. Dr. Nguyen is a pediatric oncologist and physician-scientist specializing in the discovery and preclinical development of immunotherapies for the treatment of children with neuroblastoma. Sung-Yun Pai, M.D. Sung-Yun Pai, M.D., has been appointed Chief of the Immune Deficiency Cellular Therapy Program and Medical Director of the NIH Transplantation and Cellular Therapy Clinical Program. Dr. Pai develops tailored cellular therapies for children, adolescents and young adults with genetic diseases of the blood and immune system. Drew W. Pratt, M.D. Drew W. Pratt, M.D., has joined the Laboratory of Pathology as part of CCR’s Physician-Scientist Early Investigator Program. Dr. Pratt seeks to use epigenetic and multiomic data to refine the classification of cancer and to discover novel, clinically relevant entities.
RkJQdWJsaXNoZXIy Mzc5ODkz